Qedtx.com

FGFR3 Signaling Clinical Manifestations of Achondroplasia

Achondroplasia is a rare, genetic, skeletal dysplasia. It has distinct clinical features including short stature with disproportionate shortening of limbs relative to trunk, macrocephaly with frontal bossing and midfacial hypoplasia with depressed nasal bridge, hypotonia, and joint hypermobililty. Achondroplasia may lead to multisystemic health

Actived: 3 days ago

URL: https://qedtx.com/healthcare-professionals/

Infigratinib versus gemcitabine plus cisplatin as first-line …

WebQOL will be evaluated using the EQ-5D, which measures 5 dimensions of health, including mobility, self-care, usual activities, pain/discomfort, anxiety,

Category: Health Go Health

QED Therapeutics Developing Achondroplasia Treatment Options

WebListening to people with achondroplasia, their families, and healthcare professionals to understand community needs. Pursuing research to address community needs. Sharing …

Category: Health Go Health

Infigratinib in advanced/unresectable or metastatic urothelial

WebBackground Advanced urothelial carcinoma (aUC) is an incurable disease for many patients. Platinum-based chemotherapy remains a cornerstone of therapy; a minority of patients

Category: Health Go Health

Low-dose infigratinib treatment does not lead to changes in …

WebThe planned dose of infigratinib to be tested in achondroplasia will be 0.016 mg/kg. Results. Exposure–phosphorus relationships were consistent across species …

Category: Health Go Health

Phase 3 multicenter, open-label, randomized study of …

WebPhase 3 multicenter, open-label, randomized study of infigratinib versus gemcitabine plus cisplatin in the first-line treatment of patients with advanced cholangiocarcinoma with

Category: Health Go Health

A phase II study of infigratinib (BGJ398), an FGFR-selective …

WebA phase II study of infigratinib (BGJ398), an FGFR-selective tyrosine kinase inhibitor (TKI), in patients with previously-treated advanced cholangiocarcinoma containing FGFR2 …

Category: Health Go Health

A phase II study of infigratinib (BGJ398) in previously-treated

WebA phase II study of infigratinib (BGJ398) in previously-treated advanced cholangiocarcinoma containing FGFR2 fusions Javle M,1 Kelley RK,2 Roychowdhury …

Category: Health Go Health

A background review of several generic patient-reported …

WebA background review of several generic patient-reported outcome and clinician-reported outcome measures: Selecting measures for further evaluation in a qualitative study

Category: Health Go Health

Relationship between hyperphosphatemia with infigratinib …

WebBackground Advanced urothelial carcinoma (aUC) is an incurable disease for many patients. Platinum-based chemotherapy remains a cornerstone of therapy; a minority

Category: Health Go Health

Qualitative research in children and parents of children with

WebQualitative research in children and parents of children with achondroplasia to cognitively debrief three patient-reported outcome measures and

Category: Health Go Health

Infigratinib versus gemcitabine plus cisplatin multicenter, …

WebBackground The fibroblast growth factor receptor (FGFR) family plays an important role in cholangiocarcinoma. module for patients with cholangiocarcinoma and …

Category: Health Go Health

Infigratinib versus gemcitabine plus cisplatin multicenter, …

WebInfigratinib versus gemcitabine plus cisplatin multicenter, open-label, randomized, phase 3 study in patients with advanced cholangiocarcinoma with FGFR2 gene …

Category: Health Go Health

Qualitative research in children with achondroplasia and …

WebQualitative research in children with achondroplasia and parents of children with achondroplasia: medical challenges and impacts Susan D. Mathias,1 Julie Hoover …

Category: Medical Go Health

cfDNA is an acceptable but insufficient means of …

WebBackground Previous studies indicate that genomic alterations in cell-free (cf)DNA are found in >90% of patients with metastatic urothelial cancer (mUC).1 Partial …

Category: Cancer Go Health

Assists in the development of SOPs and guidelines Facilitate …

WebPosition Summary: The Senior Medical Writer develops, writes, and edits clinical/regulatory documents (such as clinical study reports [CSRs], clinical protocols, investigator

Category: Medical Go Health

A phase II study of infigratinib (BGJ398), an FGFR-selective …

WebA phase II study of infigratinib (BGJ398), an FGFR-selective tyrosine kinase inhibitor (TKI), in patients with previously-treated advanced cholangiocarcinoma …

Category: Health Go Health

Infographic-Desktop

WebDiscovery the treatment approach in the lab Determine the tests and measurements needed for preclinical studies Learn about the condition and identify community

Category: Health Go Health